
GeoVax Reports Progress on COVID-19 Vaccine and Cancer Therapies in Q3 2024 Update
GeoVax Labs, Inc. announced advancements in its COVID-19 vaccine trials, cancer therapies, and Mpox vaccine development, along with financial results for Q3 2024. The company is preparing for a major Phase 2b trial of its COVID-19 vaccine candidate as part of the BARDA Project NextGen program.
Read full story






















